Loading…
P691Left ventricular systolic function in long term survivors of allogeneic hematopoietic stem cell transplantation
Abstract Introduction Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is increasingly utilized in young patients. Allo-HSCT usually requires myeloablative therapy that is potentially cardiotoxic. In addition, allo-HSCT survivors have a high prevalence of cardiovascular risk factors. P...
Saved in:
| Published in: | European heart journal 2019-10, Vol.40 (Supplement_1) |
|---|---|
| Main Authors: | , , , , |
| Format: | Article |
| Language: | English |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | |
| container_end_page | |
| container_issue | Supplement_1 |
| container_start_page | |
| container_title | European heart journal |
| container_volume | 40 |
| creator | Massey, R Diep, P P Ruud, E Aakhus, S Beitnes, J O |
| description | Abstract
Introduction
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is increasingly utilized in young patients. Allo-HSCT usually requires myeloablative therapy that is potentially cardiotoxic. In addition, allo-HSCT survivors have a high prevalence of cardiovascular risk factors.
Purpose
We aim to describe left ventricular systolic function in long term survivors after allo-HSCT.
Methods
This study included 104 patients, aged (mean±SD) 18±10 years at allo-HSCT, and follow-up time was 17±6 years. 74% were sufferers of malignant disease. Pre-transplantation therapies consisted of anthracyclines (AnT) in 44% and mediastinal radiotherapy in 2%. Conditioning regimes consisted of cyclophosphamide with bulsulfsan in 77%. 22% received anti-lymphocyte globulin and 6% received total body irradiation. Left ventricular (LV) function was evaluated by 2D and 3D echocardiography. Healthy controls matched for age, sex and BMI were used in group comparisons. Group comparisons were performed by t-tests and chi-square. A linear regression was used to identify contributing factors to reduced systolic LV function in allo-HSCT survivors.
Results
Most parameters of LV systolic function including 2D and 3D LV ejection fraction (LVEF), global longitudinal strain (GLS), mitral annulus excursion (MAPSE) and s' were all significantly impaired after allo-HSCT as compared to the control group. Significant (p |
| doi_str_mv | 10.1093/eurheartj/ehz747.0296 |
| format | article |
| fullrecord | <record><control><sourceid>oup_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_eurheartj_ehz747_0296</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/eurheartj/ehz747.0296</oup_id><sourcerecordid>10.1093/eurheartj/ehz747.0296</sourcerecordid><originalsourceid>FETCH-LOGICAL-c876-ac8190df7795723e6d31efb2fba5b9f3f364068aacd6536845beeedb840d1f213</originalsourceid><addsrcrecordid>eNqNkE1qwzAYREVpoWnaIxR0ASeSZcnSsoT-QaBdZNGdkeVPiYMsGUkOpKdvQkrXXQ0D82bxEHqkZEGJYkuY4g50zPsl7L7rql6QUokrNKO8LAslKn6NZoQqXgghv27RXUp7QogUVMxQ-hSKrsFmfACfY28mpyNOx5SD6w22kze5Dx73HrvgtzhDHHCa4qE_hJhwsFg7F7bg4bTewaBzGEMP-dRShgEbcA7nqH0anfZZn8_u0Y3VLsHDb87R5uV5s3or1h-v76undWFkLQptJFWks3WteF0yEB2jYNvStpq3yjLLREWE1Np0gjMhK94CQNfKinTUlpTNEb_cmhhSimCbMfaDjseGkuYsrvkT11zENWdxJ45cuDCN_0R-AJXDeis</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>P691Left ventricular systolic function in long term survivors of allogeneic hematopoietic stem cell transplantation</title><source>Oxford University Press:Jisc Collections:OUP Read and Publish 2024-2025 (2024 collection) (Reading list)</source><creator>Massey, R ; Diep, P P ; Ruud, E ; Aakhus, S ; Beitnes, J O</creator><creatorcontrib>Massey, R ; Diep, P P ; Ruud, E ; Aakhus, S ; Beitnes, J O</creatorcontrib><description><![CDATA[Abstract
Introduction
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is increasingly utilized in young patients. Allo-HSCT usually requires myeloablative therapy that is potentially cardiotoxic. In addition, allo-HSCT survivors have a high prevalence of cardiovascular risk factors.
Purpose
We aim to describe left ventricular systolic function in long term survivors after allo-HSCT.
Methods
This study included 104 patients, aged (mean±SD) 18±10 years at allo-HSCT, and follow-up time was 17±6 years. 74% were sufferers of malignant disease. Pre-transplantation therapies consisted of anthracyclines (AnT) in 44% and mediastinal radiotherapy in 2%. Conditioning regimes consisted of cyclophosphamide with bulsulfsan in 77%. 22% received anti-lymphocyte globulin and 6% received total body irradiation. Left ventricular (LV) function was evaluated by 2D and 3D echocardiography. Healthy controls matched for age, sex and BMI were used in group comparisons. Group comparisons were performed by t-tests and chi-square. A linear regression was used to identify contributing factors to reduced systolic LV function in allo-HSCT survivors.
Results
Most parameters of LV systolic function including 2D and 3D LV ejection fraction (LVEF), global longitudinal strain (GLS), mitral annulus excursion (MAPSE) and s' were all significantly impaired after allo-HSCT as compared to the control group. Significant (p<0.05) contributors to LVEF in the multivariate regression analysis were age, AnT dosage, graft versus host disease (GVHD, occurring in 67%) and hypertension (HT, occurring in 31%).
Allo-HSCT
Control
p value
n
104
55
–
Gender (female)
56 (54)
29 (53)
0.89
Age (yr)
35±12
36±11
0.44
BMI (kg/m2)
25±5
24±3
0.57
Fractional Shortening (%)
31±6
32±4
0.26
2D LVEF (%)
55±6
59±3
<0.005
3D LVEF (%)
54±5
58±3
<0.005
MAPSE (mm)
13±2
15±2
<0.005
Mean s' (mm)
81±17
89±17
<0.005
2D GLS (%)
−17±2
−20±2
<0.005
Values: mean ± SD or n (%), t-test or chi-square.
Conclusion
LV systolic function is reduced in long term survivors of allo-HSCT. Pre-transplantation AnT, HT and GVHD are significantly associated with increased risk of cardiotoxicity.
Acknowledgement/Funding
Norwegian Cancer Foundation and Norwegian ExtraFoundation for Health and Rehabilitation]]></description><identifier>ISSN: 0195-668X</identifier><identifier>EISSN: 1522-9645</identifier><identifier>DOI: 10.1093/eurheartj/ehz747.0296</identifier><language>eng</language><publisher>Oxford University Press</publisher><ispartof>European heart journal, 2019-10, Vol.40 (Supplement_1)</ispartof><rights>Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019. For permissions, please email: journals.permissions@oup.com. 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Massey, R</creatorcontrib><creatorcontrib>Diep, P P</creatorcontrib><creatorcontrib>Ruud, E</creatorcontrib><creatorcontrib>Aakhus, S</creatorcontrib><creatorcontrib>Beitnes, J O</creatorcontrib><title>P691Left ventricular systolic function in long term survivors of allogeneic hematopoietic stem cell transplantation</title><title>European heart journal</title><description><![CDATA[Abstract
Introduction
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is increasingly utilized in young patients. Allo-HSCT usually requires myeloablative therapy that is potentially cardiotoxic. In addition, allo-HSCT survivors have a high prevalence of cardiovascular risk factors.
Purpose
We aim to describe left ventricular systolic function in long term survivors after allo-HSCT.
Methods
This study included 104 patients, aged (mean±SD) 18±10 years at allo-HSCT, and follow-up time was 17±6 years. 74% were sufferers of malignant disease. Pre-transplantation therapies consisted of anthracyclines (AnT) in 44% and mediastinal radiotherapy in 2%. Conditioning regimes consisted of cyclophosphamide with bulsulfsan in 77%. 22% received anti-lymphocyte globulin and 6% received total body irradiation. Left ventricular (LV) function was evaluated by 2D and 3D echocardiography. Healthy controls matched for age, sex and BMI were used in group comparisons. Group comparisons were performed by t-tests and chi-square. A linear regression was used to identify contributing factors to reduced systolic LV function in allo-HSCT survivors.
Results
Most parameters of LV systolic function including 2D and 3D LV ejection fraction (LVEF), global longitudinal strain (GLS), mitral annulus excursion (MAPSE) and s' were all significantly impaired after allo-HSCT as compared to the control group. Significant (p<0.05) contributors to LVEF in the multivariate regression analysis were age, AnT dosage, graft versus host disease (GVHD, occurring in 67%) and hypertension (HT, occurring in 31%).
Allo-HSCT
Control
p value
n
104
55
–
Gender (female)
56 (54)
29 (53)
0.89
Age (yr)
35±12
36±11
0.44
BMI (kg/m2)
25±5
24±3
0.57
Fractional Shortening (%)
31±6
32±4
0.26
2D LVEF (%)
55±6
59±3
<0.005
3D LVEF (%)
54±5
58±3
<0.005
MAPSE (mm)
13±2
15±2
<0.005
Mean s' (mm)
81±17
89±17
<0.005
2D GLS (%)
−17±2
−20±2
<0.005
Values: mean ± SD or n (%), t-test or chi-square.
Conclusion
LV systolic function is reduced in long term survivors of allo-HSCT. Pre-transplantation AnT, HT and GVHD are significantly associated with increased risk of cardiotoxicity.
Acknowledgement/Funding
Norwegian Cancer Foundation and Norwegian ExtraFoundation for Health and Rehabilitation]]></description><issn>0195-668X</issn><issn>1522-9645</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNqNkE1qwzAYREVpoWnaIxR0ASeSZcnSsoT-QaBdZNGdkeVPiYMsGUkOpKdvQkrXXQ0D82bxEHqkZEGJYkuY4g50zPsl7L7rql6QUokrNKO8LAslKn6NZoQqXgghv27RXUp7QogUVMxQ-hSKrsFmfACfY28mpyNOx5SD6w22kze5Dx73HrvgtzhDHHCa4qE_hJhwsFg7F7bg4bTewaBzGEMP-dRShgEbcA7nqH0anfZZn8_u0Y3VLsHDb87R5uV5s3or1h-v76undWFkLQptJFWks3WteF0yEB2jYNvStpq3yjLLREWE1Np0gjMhK94CQNfKinTUlpTNEb_cmhhSimCbMfaDjseGkuYsrvkT11zENWdxJ45cuDCN_0R-AJXDeis</recordid><startdate>20191001</startdate><enddate>20191001</enddate><creator>Massey, R</creator><creator>Diep, P P</creator><creator>Ruud, E</creator><creator>Aakhus, S</creator><creator>Beitnes, J O</creator><general>Oxford University Press</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20191001</creationdate><title>P691Left ventricular systolic function in long term survivors of allogeneic hematopoietic stem cell transplantation</title><author>Massey, R ; Diep, P P ; Ruud, E ; Aakhus, S ; Beitnes, J O</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c876-ac8190df7795723e6d31efb2fba5b9f3f364068aacd6536845beeedb840d1f213</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Massey, R</creatorcontrib><creatorcontrib>Diep, P P</creatorcontrib><creatorcontrib>Ruud, E</creatorcontrib><creatorcontrib>Aakhus, S</creatorcontrib><creatorcontrib>Beitnes, J O</creatorcontrib><collection>CrossRef</collection><jtitle>European heart journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Massey, R</au><au>Diep, P P</au><au>Ruud, E</au><au>Aakhus, S</au><au>Beitnes, J O</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>P691Left ventricular systolic function in long term survivors of allogeneic hematopoietic stem cell transplantation</atitle><jtitle>European heart journal</jtitle><date>2019-10-01</date><risdate>2019</risdate><volume>40</volume><issue>Supplement_1</issue><issn>0195-668X</issn><eissn>1522-9645</eissn><abstract><![CDATA[Abstract
Introduction
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is increasingly utilized in young patients. Allo-HSCT usually requires myeloablative therapy that is potentially cardiotoxic. In addition, allo-HSCT survivors have a high prevalence of cardiovascular risk factors.
Purpose
We aim to describe left ventricular systolic function in long term survivors after allo-HSCT.
Methods
This study included 104 patients, aged (mean±SD) 18±10 years at allo-HSCT, and follow-up time was 17±6 years. 74% were sufferers of malignant disease. Pre-transplantation therapies consisted of anthracyclines (AnT) in 44% and mediastinal radiotherapy in 2%. Conditioning regimes consisted of cyclophosphamide with bulsulfsan in 77%. 22% received anti-lymphocyte globulin and 6% received total body irradiation. Left ventricular (LV) function was evaluated by 2D and 3D echocardiography. Healthy controls matched for age, sex and BMI were used in group comparisons. Group comparisons were performed by t-tests and chi-square. A linear regression was used to identify contributing factors to reduced systolic LV function in allo-HSCT survivors.
Results
Most parameters of LV systolic function including 2D and 3D LV ejection fraction (LVEF), global longitudinal strain (GLS), mitral annulus excursion (MAPSE) and s' were all significantly impaired after allo-HSCT as compared to the control group. Significant (p<0.05) contributors to LVEF in the multivariate regression analysis were age, AnT dosage, graft versus host disease (GVHD, occurring in 67%) and hypertension (HT, occurring in 31%).
Allo-HSCT
Control
p value
n
104
55
–
Gender (female)
56 (54)
29 (53)
0.89
Age (yr)
35±12
36±11
0.44
BMI (kg/m2)
25±5
24±3
0.57
Fractional Shortening (%)
31±6
32±4
0.26
2D LVEF (%)
55±6
59±3
<0.005
3D LVEF (%)
54±5
58±3
<0.005
MAPSE (mm)
13±2
15±2
<0.005
Mean s' (mm)
81±17
89±17
<0.005
2D GLS (%)
−17±2
−20±2
<0.005
Values: mean ± SD or n (%), t-test or chi-square.
Conclusion
LV systolic function is reduced in long term survivors of allo-HSCT. Pre-transplantation AnT, HT and GVHD are significantly associated with increased risk of cardiotoxicity.
Acknowledgement/Funding
Norwegian Cancer Foundation and Norwegian ExtraFoundation for Health and Rehabilitation]]></abstract><pub>Oxford University Press</pub><doi>10.1093/eurheartj/ehz747.0296</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0195-668X |
| ispartof | European heart journal, 2019-10, Vol.40 (Supplement_1) |
| issn | 0195-668X 1522-9645 |
| language | eng |
| recordid | cdi_crossref_primary_10_1093_eurheartj_ehz747_0296 |
| source | Oxford University Press:Jisc Collections:OUP Read and Publish 2024-2025 (2024 collection) (Reading list) |
| title | P691Left ventricular systolic function in long term survivors of allogeneic hematopoietic stem cell transplantation |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T03%3A18%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=P691Left%20ventricular%20systolic%20function%20in%20long%20term%20survivors%20of%20allogeneic%20hematopoietic%20stem%20cell%20transplantation&rft.jtitle=European%20heart%20journal&rft.au=Massey,%20R&rft.date=2019-10-01&rft.volume=40&rft.issue=Supplement_1&rft.issn=0195-668X&rft.eissn=1522-9645&rft_id=info:doi/10.1093/eurheartj/ehz747.0296&rft_dat=%3Coup_cross%3E10.1093/eurheartj/ehz747.0296%3C/oup_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c876-ac8190df7795723e6d31efb2fba5b9f3f364068aacd6536845beeedb840d1f213%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/eurheartj/ehz747.0296&rfr_iscdi=true |